Consumer Health Neurology

Merz Therapeutics Receives TGA Approval for XEOMIN® in Australia

This marks a significant milestone as XEOMIN® is the first approved neurotoxin for the treatment of this condition in the Australian market. Addit...

 November 23, 2023 | News

Fujitsu Licenses Topological Data Analysis Tech to Bay Area Startup Delight Health for Mental Health Solutions

Fujitsu Limited and Delight Health, a Bay Area startup,  announced that Fujitsu will license its Topological Data Analysis (TDA) technology to Delight...

 November 20, 2023 | News

Aquinnah Pharmaceuticals Advances Alzheimer's Tauopathy Program

Aquinnah Pharmaceuticals announced preclinical research findings for a novel therapeutic designed to slow or stop the progression of Alzheimer's disea...

 October 31, 2023 | News

Clario's Opal® Technology Drives Breakthrough in Parkinson's Disease at University of Oxford

Clario's Precision Motion Opal® wearable sensor technology detects early Parkinson's disease (PD) progression in a Univ...

 October 30, 2023 | News

PharmaKure submits for Alzheimer's Disease Combined Drug Clinical Trial

 PharmaKure, a clinical stage pharmaceutical company developing precision medicines for Alzheimer’s Disease and other neurodegenerative diseases...

 October 25, 2023 | News

Rimegepant Now Available in Hong Kong as First Asian Market for Migraine Management

"As the first market in Asia, we are pleased to bring to Hong Kong this medication for migraine, as we understand how migraine can adversely...

 October 02, 2023 | News

Bionomics Reports Positive Phase 2b Results for BNC210 in Post-Traumatic Stress Disorder Trial

ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant reduction in total PTSD symptom severity at 12 weeks. St...

 September 29, 2023 | News

Cellectricon expands neuroscience contract research portfolio with new Neuroplasticity services

Cellectricon, a services provider dedicated to advancing neuroscience drug discovery,  announced the launch of a new service module for neuroplasticit...

 September 27, 2023 | News

Actinogen optimizes XanaMIA Phase 2b Alzheimer's disease trial design

Changes to the XanaMIA protocol reduce cost by AUD 30 million over the next two years and speed time to initial results while preserving the 36-week design...

 September 27, 2023 | News

Ascletis Completes Enrollment for Glioblastoma Treatment Trial

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis")  announces the completion of enrollment of 120 patients in the Phase III registration clinical trial of ...

 September 27, 2023 | News

Cerecin strengthens position in neurometabolism with addition to pipeline

Cerecin completes in-licensing of an investigational radiolabelled tracer 18FBHB, CER-022, for development and use in positron emission tomography (...

 September 20, 2023 | News

Oscotec/ADEL Receives FDA Clearance for Alzheimer's Treatment IND Application (ADEL-Y01)

Oscotec and ADEL are jointly developing a novel disease-modifying immunotherapy agent (ADEL-Y01) targeting tau protein accumulation in the AD brain. ADEL-Y...

 September 15, 2023 | News

IBT and ATLATL Join Forces to Tackle Challenges in Brain Health

Starting out of China, IBT Global is a rising player in Digital Therapeutics (DTx) with an experienced cross-functional team operating at the intersection ...

 September 05, 2023 | News

Salvia BioElectronics Treats First Patient with Neuromodulation for Severe Migraine in Australia

The first patient, a 29-year-old woman from Australia who has suffered from debilitating headaches since the age of 14, experienced immediate and...

 August 24, 2023 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in